Skip to main content
Retour
Watch Compare

Allarity Therapeutics, Inc.

Qualité des données : 83%
ALLR
NASDAQ Manufacturing Chemicals
1,23 €
▼ 0,02 € (-1,21%)
6 months return
—
Momentum
Neutral
ROE
-92,90%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-92,90%
En dessous de la moyenne du secteur (-54,68%)
ROIC-82,37%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio2,33
Interest Coverage-68,14

Valorisation

P/E Ratio
-1,63 TTM
-1,29 NTM
En dessous de la moyenne du secteur (-1,49)
P/B Ratio1,52
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -14,83 M

Price History

Tendances Financières

Objectif de Cours des Analystes

1 analyste
Buy
+695.9%
upside to target
Actuel
1,23 €
Consensus Target
9,75 €
9,75 €
Bas
9,75 €
Haut
Prévisions
P/E Prévisionnel
-1,29
BPA Prévisionnel
-0,97 €
CA Est.
0,0

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,22 € · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -0,25 € -0,15 € -0,19 € -0,21 € — —
Estimate — -0,21 € -0,23 € -0,22 € -0,22 € -0,25 €
Surprise — +28,57% +17,39% +4,55% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -92,90% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -11,23 M
ROE -92,90% ROA -53,48%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14,83 M
ROIC -82,37% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2,33
Debt / Equity N/A Current Ratio 2,33
Interest Coverage -68,14 Asset Turnover N/A
Working Capital 11,68 M Tangible Book Value 12,01 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -1,63 · EV/EBITDA: N/A
P/E Ratio -1,63 Forward P/E -1,29
P/B Ratio 1,52 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -81,16%
Market Cap 18,27 M Enterprise Value 1,38 M

Per Share

EPS: N/A · FCF/Share: -0,94
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0,94 OCF / Share -0,94
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 132,03% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 132,03%
SBC-Adj. FCF -15,28 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -11,23 M -24,52 M -11,90 M -16,06 M -26,65 M
EPS (Diluted) — — -10,26 -2,21 —
Gross Profit — — -2,27 M — —
Operating Income -12,61 M -27,24 M -17,13 M -34,46 M -26,56 M
EBITDA — — — — —
R&D Expenses 6,60 M 6,10 M 7,10 M 6,93 M 14,20 M
SG&A Expenses — — — — —
D&A — 9 000,0 37 000,0 60 000,0 106 000,0
Interest Expense 185 000,0 653 000,0 498 000,0 12 000,0 93 000,0
Income Tax 0,0 -381 000,0 83 000,0 -1,52 M 133 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18,26 M 22,65 M 11,86 M 14,54 M 49,63 M
Total Liabilities 8,43 M 10,84 M 14,61 M 12,65 M 30,85 M
Shareholders' Equity 9,83 M 11,81 M -2,75 M -113 000,0 18,15 M
Total Debt — 2,69 M — 2,64 M —
Cash & Equivalents 14,69 M 19,53 M 166 000,0 — —
Current Assets 17,93 M 22,34 M 1,97 M 4,97 M 21,05 M
Current Liabilities 8,43 M 10,84 M 14,17 M 11,22 M 20,72 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -1,6 -1,5
P/B 1,5 1,6
ROE % -92,9 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3